Table 2.
Subject characteristics
| Variable | LHC | T2DM |
|---|---|---|
| n | 18 (7 ♂) | 9 (5 ♂) |
| Age, year | 31 ± 2 | 58 ± 4a |
| Weight, kg | 62.8 ± 2.8 | 104.7 ± 7.7a |
| BMI, kg/m2 | 22.3 ± 0.6 | 34.1 ± 2.1a |
| Body fat, % | 25.3 ± 1.4 | 40.2 ± 2.8a |
| Systolic BP, mmHg | 116 ± 4 | 135 ± 6a |
| Diastolic BP, mmHg | 69 ± 3 | 79 ± 4 |
| FPG, mg/dL | 91 ± 1 | 127 ± 12a |
| FPI, μU/mL | 8.4 ± 1.4 | 8.0 ± 1.0 |
| HbA1c, % | 5.4 ± 0.1 | 7.2 ± 0.6a |
| 2 h‐OGTT, mg/dL | 101 ± 3 | 233 ± 39a |
| GDR, mg/kg/min | 6.6 ± 0.4 | 2.8 ± 0.3a |
| Clamp Insulin, μU/mL | 91.0 ± 10.2 | 89.2 ± 6.0 |
| Total chol, mg/dL | 156 ± 6 | 152 ± 10 |
| HDL, mg/dL | 63 ± 4 | 53 ± 5 |
| LDL, mg/dL | 79 ± 7 | 79 ± 7 |
| VLDL, mg/dL | 15 ± 1 | 21 ± 5 |
| TG, mg/dL | 74 ± 6 | 104 ± 26 |
Data represent mean ± SEM. a.u., arbitrary units; BMI, body mass index; chol, cholesterol; fat%, percentage of body fat; FPG, fasting plasma glucose; FPI, fasting plasma insulin; GDR; hyperinsulinemic‐euglycemic clamp‐derived glucose disposal rate; clamp insulin, steady‐state plasma insulin concentrations at end of clamp; HbA1c, hemoglobin A1c; LHC, lean healthy control; OGTT, oral glucose tolerance test; TG, triglycerides.
a
Significant difference between LHC and T2DM (P < 0.05).